Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

KARYOPHARM THERAPEUTICS INC.

(KPTI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Expanded Partnership with Medidata Supports Karyopharm's Mission to Develop First-in-Class Therapeutics

03/11/2021 | 06:38am EDT

Adoption of additional technology solutions demonstrates commitment to patients with cancer and other serious diseases.

Medidata, a Dassault Systemes company and the global leader in creating end-to-end solutions to support the entire clinical development process, today announced its expanded partnership with Karyopharm Therapeutics (NASDAQ: KPTI). In 2014, Karyopharm selected one Medidata technology solution for a single study. Today, the company is leveraging 10 solutions in Medidata Rave Clinical Cloud in more than 15 clinical studies focused on hematologic malignancies and solid tumors.

'Medidata is pleased to play a key role in supporting Karyopharm's mission of bringing novel therapies to market, providing hope for patients,' said Glen de Vries, co-founder and co-CEO, Medidata. 'This agreement is a clear demonstration of our shared mission to advance analytics and technology to make a difference in health care.'

With Medidata solutions, Karyopharm is able to:

Centralize operations, eliminate manual data entry, and operate with a clear view of all cross-application data in one place

Simplify and customize reporting within or across studies and leverage over 30 standard reports

Reduce complexity by standardizing and improving data quality with powerful artificial intelligence and machine learning algorithms that automatically manage the complexity of clinical data

'Medidata continues to be an important strategic partner for Karyopharm by providing a cutting-edge technological infrastructure that helps us reach our clinical trial goals,' said Kristan Gallitano, senior vice president, Development Operations at Karyopharm. 'Medidata provides us the flexible, scalable technology and support we need to meet the evolving challenges of drug development.'

Medidata is a wholly owned subsidiary of Dassault Systemes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.

About Medidata

Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate evidence and insights to help pharmaceutical, biotech, medical device, and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,400 customers and partners access the world's most-used platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systemes company (Euronext Paris: #13065, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata, The Operating System for Life SciencesTM.

Medidata, Rave, and myMedidata are registered trademarks of Medidata Solutions, Inc., a wholly-owned subsidiary of Dassault Systemes.

About Dassault Systemes

Dassault Systemes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating 'virtual experience twins' of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production.

Dassault Systemes' 20,000 employees are bringing value to more than 270,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit https://www.3ds.com

(C) 2021 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
DASSAULT SYSTÈMES SE -0.10% 200.3 Real-time Quote.20.55%
KARYOPHARM THERAPEUTICS INC. -0.77% 10.35 Delayed Quote.-33.14%
All news about KARYOPHARM THERAPEUTICS INC.
06/10KARYOPHARM THERAPEUTICS  : Announces XPOVIO (selinexor) Data to be Presented at ..
AQ
06/09KARYOPHARM THERAPEUTICS  : Announces XPOVIO® (selinexor) Data to be Presented at..
PR
06/08KARYOPHARM THERAPEUTICS  : Announces Key Changes to Its Commercial Leadership Te..
PR
06/04KARYOPHARM THERAPEUTICS  : Announces XPOVIO (selinexor) Is Now Available in Addi..
AQ
06/03KARYOPHARM THERAPEUTICS  : Receives Conditional Marketing Authorization in the U..
AQ
06/03KARYOPHARM THERAPEUTICS  : Announces XPOVIO® (selinexor) Is Now Available in Add..
PR
06/02KARYOPHARM THERAPEUTICS  : Reports Inducement Grants Under Nasdaq Listing Rule 5..
AQ
06/02KARYOPHARM THERAPEUTICS  : Secures UK Conditional Marketing Approval for Nexpovi..
MT
06/02KARYOPHARM THERAPEUTICS  : Receives Conditional Marketing Authorization in the U..
PR
06/01KARYOPHARM THERAPEUTICS  : Reports Inducement Grants Under Nasdaq Listing Rule 5..
PR
More news
Financials (USD)
Sales 2021 125 M - -
Net income 2021 -217 M - -
Net Debt 2021 31,5 M - -
P/E ratio 2021 -3,67x
Yield 2021 -
Capitalization 777 M 777 M -
EV / Sales 2021 6,48x
EV / Sales 2022 3,71x
Nbr of Employees 432
Free-Float 90,2%
Chart KARYOPHARM THERAPEUTICS INC.
Duration : Period :
Karyopharm Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KARYOPHARM THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 10,35 $
Average target price 24,70 $
Spread / Average Target 139%
EPS Revisions
Managers and Directors
NameTitle
Richard A. Paulson President, Chief Executive Officer & Director
Michael P. Mason Chief Financial & Accounting Officer, Treasurer
Sharon Shacham Chief Scientific Officer
Jatin Shah Chief Medical Officer & Executive Vice President
Yosef Landesman Senior VP-Research & Translational Medicine
Sector and Competitors
1st jan.Capitalization (M$)
KARYOPHARM THERAPEUTICS INC.-33.14%777
GILEAD SCIENCES, INC.14.40%84 093
WUXI APPTEC CO., LTD.36.51%68 536
BIONTECH SE181.53%57 117
REGENERON PHARMACEUTICALS9.66%55 301
VERTEX PHARMACEUTICALS-20.66%48 892